Trazodone is approved by the FDA to treat major depressive disorder in adults, but the majority of prescriptions written for it today are actually for insomnia and sleep disturbances. That split between what a drug is officially for and what it is actually used for makes trazodone one of the more interesting medications in modern psychiatry. Its effects shift depending on the dose, it interacts with a surprisingly wide range of brain receptors, and it has found its way into clinical niches that range from anxiety to dementia-related agitation to post-surgical recovery in dogs.
Depression and How It Stacks Up
Trazodone belongs to a class called serotonin antagonist and reuptake inhibitors, or SARIs. That class label sounds similar to the better-known SSRIs, but the mechanism is meaningfully different. Rather than primarily blocking the reabsorption of serotonin the way an SSRI does, trazodone works across multiple receptor systems, including serotonin, adrenaline-related, and histamine receptors, which accounts for its wide range of effects.1PubMed Central. A narrative review on trazodone as a multimodal and multifunctional antidepressant: clinical relevance of formulations, dosing, and pharmacokinetic/pharmacodynamic targets In head-to-head comparisons with other antidepressants, trazodone’s effectiveness against depression symptoms is broadly comparable.2PubMed Central. Role of trazodone in treatment of major depressive disorder: an update
A randomized, double-blind trial of an extended-release form tested against placebo found that depression scores dropped significantly more in the trazodone group, with an average improvement of about 11 points on a standard depression scale versus about 9 for placebo.3Psychiatry (Edgemont). Extended-release Trazodone in Major Depressive Disorder: A Randomized, Double-blind, Placebo-controlled Study That gap may not sound enormous, but it is in line with many approved antidepressants. Where trazodone has a particular edge over some competitors is in treating depression that comes with insomnia, since the same drug can address both problems at once rather than requiring a separate sleep aid.2PubMed Central. Role of trazodone in treatment of major depressive disorder: an update
The main reason trazodone lost ground to SSRIs as a first-line antidepressant for depression alone is its side-effect profile. At the higher doses needed to treat depression (typically 150 to 300 mg or more per day), sedation and dizziness become more pronounced. Many clinicians prescribe it as an add-on to another antidepressant rather than as the sole treatment, letting a patient take a standard SSRI or SNRI for mood while using low-dose trazodone at bedtime for sleep.
The Sleep Effect and Why Dose Matters
Trazodone’s most common real-world use is as a sleep aid, typically at doses far below those used for depression. Research on receptor occupancy suggests that a dose of around 50 mg is enough to block the specific receptors responsible for the sedative effect.4PubMed. Evaluating the dose-dependent mechanism of action of trazodone by estimation of occupancies for different brain neurotransmitter targets Higher doses are needed before you start seeing meaningful antidepressant activity. This dose-dependent behavior is one of the drug’s most distinctive features: the same medication does genuinely different things at different doses.
A systematic review and meta-analysis pooling sleep-lab data found that trazodone increased total sleep time by roughly 40 minutes compared with placebo, cut the time it took to fall asleep by about 19 minutes, and reduced the number of nighttime awakenings. It also boosted deep sleep (the restorative stage sometimes called slow-wave sleep) while decreasing the lighter, more fragmented stage of drowsiness.5Scientific Reports. Trazodone changed the polysomnographic sleep architecture in insomnia disorder: a systematic review and meta-analysis An earlier study found a similar pattern, noting that trazodone halved the frequency of nighttime arousals and increased deep sleep, though in that trial total sleep duration itself did not change.6PubMed Central. Trazodone enhances sleep in subjective quality but not in objective duration
That last point is worth pausing on. Some of trazodone’s sleep benefit seems to be about quality rather than raw hours. You may not necessarily sleep two hours longer, but the sleep you do get tends to be deeper, with fewer interruptions. People often report feeling like they slept better even when a sleep-lab recording shows only a modest change in total time. The boost in deep sleep and the drop in arousals are likely doing most of that perceptual work.
One practical advantage of trazodone over many dedicated sleep medications is that it is not classified as a controlled substance. Drugs like zolpidem and benzodiazepines carry concerns about dependence and tolerance, and many clinicians are cautious about prescribing them long-term. Trazodone does not carry the same dependency risk, which is part of why it has become a go-to for chronic insomnia. A systematic review comparing zolpidem and trazodone in older adults concluded that while zolpidem was more effective at eliminating insomnia outright, trazodone was better suited for chronic insomnia in people who also had anxiety or depression, and it had a more favorable safety profile overall.7Caderno Pedagógico. Effectiveness of zolpidem vs trazodone for sleep disorders in older adults: a systematic review
Anxiety
Trazodone is not FDA-approved for anxiety disorders, but evidence supports its use there as well. A controlled trial comparing trazodone against imipramine (a tricyclic antidepressant), diazepam (a benzodiazepine), and placebo in generalized anxiety disorder found that from week three through week eight, trazodone achieved anxiolytic effects comparable to diazepam. Among patients who completed the trial, about 69% of the trazodone group showed moderate to marked improvement, versus 66% for diazepam and 47% for placebo.8JAMA Psychiatry. Antidepressants for the Treatment of Generalized Anxiety Disorder: A Placebo-Controlled Comparison of Imipramine, Trazodone, and Diazepam Tension, apprehension, and worry responded particularly well to the antidepressant medications in that trial.
This anxiety-reduction effect likely comes from the same receptor-blocking activity that helps with sleep. At low to moderate doses, trazodone dampens the brain’s arousal systems, which can quiet the physical and psychological components of anxiety. Clinicians sometimes use it as a bridge for patients weaning off benzodiazepines, since it offers some anti-anxiety benefit without the same dependency risk.
Agitation in Dementia
One of trazodone’s more controversial off-label uses is managing agitation and behavioral disturbances in people with dementia. In practice, some palliative care guidelines list it as a reasonable first choice for acute irritability and agitation in Alzheimer’s disease, noting that it can reduce agitation and insomnia with onset in about 30 to 60 minutes at low doses.9PubMed. Management of Behavioral Disturbances in Dementia: Part 2 Pharmacologic
The formal evidence, however, is thin. A Cochrane systematic review found that trazodone was not associated with statistically significant improvements in behavioral symptoms of dementia compared with placebo, whether measured by agitation scales, caregiver impressions, or cognitive function tests. The reviewers concluded there was insufficient evidence to recommend trazodone for this purpose.10PubMed. Trazodone for agitation in dementia The gap between clinical practice and the formal evidence base is striking. Many clinicians still reach for trazodone in these situations because the alternatives, particularly antipsychotics, carry their own serious risks for older adults with dementia. Trazodone at low doses tends to be well tolerated in this population, even if the evidence that it specifically reduces agitation is not strong.
Risks for Older Adults
While trazodone is generally considered safer than many alternatives for elderly patients, it is not without real hazards in this group. The biggest concern is orthostatic hypotension, the sudden drop in blood pressure when you stand up, which can lead to dizziness, fainting, and falls. A study of geriatric outpatients with high blood pressure found that trazodone users had significantly greater blood-pressure drops upon standing compared with non-users. The rate of syncope and falls was dramatically higher among trazodone users: about 58% versus 21% in those not taking the drug.11PubMed Central. Trazodone and Risk of Orthostatic Hypotension, Syncope and Falls in Geriatric Outpatients with Hypertension A separate study in a long-term care setting found that falls were the most common adverse event among trazodone users, affecting about 30% of participants.12PubMed. Real-World Use of Trazodone in Older Persons in Long Term Care Setting: A Retrospective Study
For context, competing sleep medications carry their own fall risks. A study comparing zolpidem and trazodone initiation in hemodialysis patients found that starting zolpidem was associated with a higher risk of fall-related fractures requiring hospitalization than starting trazodone.13PubMed Central. Zolpidem Versus Trazodone Initiation and the Risk of Fall-Related Fractures among Individuals Receiving Maintenance Hemodialysis So while trazodone does increase fall risk, it may still be a relatively safer sedating option than some alternatives in certain populations. The take-home for older adults or their caregivers: start at the lowest effective dose, take it at bedtime rather than during the day, and be especially careful about getting up at night.
Trazodone and Alcohol Use Disorder
Insomnia is extremely common during and after alcohol detoxification, and clinicians have long turned to trazodone to help with this. It does work for the sleep problem in the short term. A double-blind trial found that trazodone improved sleep quality significantly during the period it was being taken, but after it was stopped, sleep quality returned to the same level as placebo.14PubMed Central. Trazodone For Sleep Disturbance After Alcohol Detoxification: A Double-Blind, Placebo-Controlled Trial
More concerning is emerging evidence that trazodone may actually increase alcohol cravings and drinking in people with alcohol use disorder. The culprit appears to be one of trazodone’s metabolites, a breakdown product called mCPP, which has been identified in multiple trials as a trigger for increased alcohol craving and use.15PubMed Central. Rethinking trazodone for insomnia in alcohol use disorder This is a genuine clinical concern that is only recently getting the attention it deserves. If you are in recovery from alcohol dependence and your doctor prescribes trazodone for sleep, it is worth discussing this research.
The mCPP Metabolite and Drug Interactions
That metabolite, mCPP, deserves a closer look because it explains several of trazodone’s quirks. When your liver processes trazodone, the enzyme CYP3A4 converts it into mCPP, which is pharmacologically active and has its own effects on serotonin receptors.16PubMed. Metabolism of the antidepressant trazodone to its active metabolite m-chlorophenylpiperazine by CYP3A4 from human sources The mCPP metabolite is itself broken down by a second enzyme, CYP2D6.17PubMed Central. CYP2D6 Phenotype as a Predictor of Adverse Drug Reactions in Patients Treated With Trazodone: An Explorative Pharmacogenetic Study
This two-enzyme relay has practical consequences. If you take other medications that compete for CYP3A4, such as certain antifungals, HIV medications, or even grapefruit juice in quantity, the balance of trazodone and mCPP in your system can shift unpredictably. Strong CYP3A4 inhibitors can slow the conversion, increasing trazodone levels. And people who are genetically slow metabolizers through the CYP2D6 pathway may accumulate more mCPP, potentially experiencing more side effects like nausea, dizziness, and restlessness.17PubMed Central. CYP2D6 Phenotype as a Predictor of Adverse Drug Reactions in Patients Treated With Trazodone: An Explorative Pharmacogenetic Study If trazodone gives you unexpected side effects at doses that should be well tolerated, your individual enzyme profile could be part of the explanation.
Side Effects Beyond Sedation
The most common side effect at any dose is daytime drowsiness, especially in the first week or two. For people taking trazodone specifically for sleep, that sedation is the point, but it can linger into the morning if the dose is too high or taken too late. Other relatively common side effects include dry mouth, dizziness, and headache.
The side effect that gets the most alarmed attention, especially in online forums, is priapism, a prolonged, painful erection. This is real but genuinely rare. It occurs because trazodone’s alpha-adrenergic receptor blocking affects smooth muscle tone, including in penile tissue. Estimates vary, but the incidence is typically quoted at roughly 1 in 6,000 to 1 in 8,000 male patients. It is serious when it happens, because priapism lasting more than four hours requires emergency treatment to prevent permanent damage. The rarity means most men will never experience this, but anyone prescribed trazodone should know it is a possibility and understand that it requires immediate medical attention.
Trazodone can also cause slight changes in heart rhythm at higher doses, particularly a small prolongation of the QT interval. For most people this is clinically insignificant, but it matters if you already take other medications that affect the QT interval or have an underlying heart-rhythm condition. Your prescriber should screen for these interactions.
How Trazodone Became So Widely Prescribed
Trazodone was developed in Italy in the 1960s and became the first non-tricyclic antidepressant approved for use in the United States, gaining approval in 1981. At the time, it was positioned as a safer alternative to the older tricyclic antidepressants, which had potentially lethal overdose risks and a heavy side-effect burden. When the SSRIs arrived in the late 1980s and quickly dominated the antidepressant market, trazodone’s use as a primary antidepressant faded. But clinicians noticed that patients taking trazodone slept much better, and a secondary career as a sleep aid was born.
Today, off-label prescribing for insomnia dwarfs its use for depression. This is somewhat unusual in medicine. Most drugs that are prescribed off-label for a secondary condition still get the majority of their prescriptions for the approved indication. Trazodone flipped that ratio long ago. The off-label status means that the evidence base for trazodone’s sleep effects, while substantial, has not been through the same rigorous approval process that a drug specifically developed and marketed for insomnia would face. No pharmaceutical company has strong financial incentive to run the expensive trials needed for a formal insomnia indication on a drug that has been generic for decades.
Trazodone in Veterinary Medicine
One of the more surprising chapters in trazodone’s story is its widespread use in dogs and cats. Veterinarians prescribe it for anxiety, to help with travel and vet-visit stress, and to facilitate calm behavior during recovery from surgery. A clinical study of dogs recovering from orthopedic surgery found that roughly 90% of owners reported that their dogs showed moderate to extreme improvement in calmness and tolerance of confinement when given trazodone during the 8 to 12 week recovery period. The drug was well tolerated, even alongside painkillers and antibiotics, and no dogs were withdrawn from the study due to side effects.18PubMed Central. The Use of Trazodone to Facilitate Post-Surgical Confinement in Dogs
The veterinary applications mirror the human ones in an interesting way. Just as low-dose trazodone acts primarily as a sedative and anxiolytic in people, it works similarly in animals. Veterinary behaviorists use it for anxiety disorders in pets, for calming animals before stressful events like thunderstorms or veterinary visits, and for managing agitation in hospitalized patients.19Journal of Veterinary Behavior. The use of trazodone to facilitate calm behavior after elective orthopedic surgery in dogs: Results and lessons learned from a clinical trial If your vet has prescribed trazodone for your dog, it is the same drug, used for many of the same general reasons, with a similarly favorable safety profile at appropriate doses.
The Neuroprotection Question
A more speculative line of research involves trazodone’s potential role in protecting the brain against neurodegeneration. The receptor-occupancy research suggesting that low doses block receptors tied to hypnotic effects also raised the possibility that those same doses could provide a protective effect against neuroinflammation and neurodegeneration, a finding the authors noted could be beneficial in dementia.4PubMed. Evaluating the dose-dependent mechanism of action of trazodone by estimation of occupancies for different brain neurotransmitter targets This is early-stage thinking, not a treatment recommendation. No large clinical trial has demonstrated that trazodone prevents or slows cognitive decline. But the idea that a cheap, well-understood generic drug might have neuroprotective properties at doses people are already taking for sleep is the kind of finding that tends to generate further research. It is worth watching, not worth acting on prematurely.
The broader story of trazodone is really a story about how a drug’s life can diverge from its original purpose. Designed as an antidepressant, eclipsed by SSRIs, reinvented as a sleep aid, now being explored for brain protection and prescribed for anxious dogs, trazodone has had more career pivots than most medications. For the person considering it today, the practical reality is that it is a well-established drug with genuine evidence behind its use for both depression and insomnia, a reasonable safety profile for most adults, and specific risks that are manageable if you and your doctor know to watch for them.